文献速递特殊人群用药治疗药物监测与药物基因组学

成人肾移植受者他克莫司个体化起始剂量的群体药代动力学模型

A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients.
PubMed 文献 · Br J Clin Pharmacol · 2019-01-17

本研究基于337例成人肾移植受者术后3个月内采集的4527份他克莫司血样,采用非线性混合效应模型构建二室群体药代动力学模型,并据此建立个体化起始剂量计算工具。年龄、体表面积、CYP3A4及CYP3A5基因型被纳入起始剂量模型,可解释30%的清除率变异,模型经内部和外部验证有效。

要点

  • 他克莫司清除率受年龄、体表面积、血清肌酐、白蛋白、红细胞压积及CYP3A4/CYP3A5基因型显著影响。
  • CYP3A5表达者他克莫司清除率显著升高160%,CYP3A4*22携带者清除率显著降低80%。
  • 基于年龄、体表面积和CYP3A4/CYP3A5基因型的模型可用于计算肾移植术后早期他克莫司个体化起始剂量。

核心结论

  • 年龄、体表面积、CYP3A4和CYP3A5基因型是预测他克莫司药代动力学的重要协变量,可解释30%的清除率变异。
  • 该模型能基于上述参数计算最佳他克莫司起始剂量,可用于肾移植术后早期个体化给药。

研究设计与样本

  • 研究收集肾移植术后前3个月的他克莫司暴露数据,共纳入337例成人肾移植受者的4527份他克莫司血样。
  • 采用非线性混合效应模型进行群体药代动力学分析,评估人口学、临床和遗传参数作为协变量。

主要发现

  • 数据最佳拟合二室模型,平均吸收速率常数3.6 h-1,清除率23.0 l h-1(个体间变异39%),中央室分布容积692 l(个体间变异49%),外周室分布容积5340 l(个体间变异53%)。
  • 清除率加入 occasions 间变异为14%。
  • 较高的体表面积、较低的血清肌酐、较年轻的年龄、较高的白蛋白和较低的红细胞压积被确定为提高他克莫司清除率的协变量。
  • CYP3A5表达者他克莫司清除率显著升高160%,CYP3A4*22携带者清除率显著降低80%。

关键数值与推荐

  • 第二模型纳入年龄、体表面积、CYP3A4和CYP3A5基因型用于个体化他克莫司起始剂量计算。
  • 两个模型均成功通过内部和外部验证。

临床怎么用

  • 临床可基于年龄、体表面积及CYP3A4/CYP3A5基因型使用该模型计算肾移植术后早期他克莫司个体化起始剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The aims of this study were to describe the pharmacokinetics of tacrolimus immediately after kidney transplantation, and to develop a clinical tool for selecting the best starting dose for each patient. METHODS: Data on tacrolimus exposure were collected for the first 3 months following renal transplantation. A population pharmacokinetic analysis was conducted using nonlinear mixed-effects modelling. Demographic, clinical and genetic parameters were evaluated as covariates. RESULTS: A total of 4527 tacrolimus blood samples collected from 337 kidney transplant recipients were available. Data were best described using a two-compartment model. The mean absorption rate was 3.6 h-1 , clearance was 23.0 l h-1 (39% interindividual variability, IIV), central volume of distribution was 692 l (49% IIV) and the peripheral volume of distribution 5340 l (53% IIV). Interoccasion variability was added to clearance (14%). Higher body surface area (BSA), lower serum creatinine, younger age, higher albumin and lower haematocrit levels were identified as covariates enhancing tacrolimus clearance. Cytochrome P450 (CYP) 3A5 expressers had a significantly higher tacrolimus clearance (160%), whereas CYP3A4*22 carriers had a significantly lower clearance (80%). From these significant covariates, age, BSA, CYP3A4 and CYP3A5 genotype were incorporated in a second model to individualize the tacrolimus starting dose: [Formula: see text] Both models were successfully internally and externally validated. A clinical trial was simulated to demonstrate the added value of the starting dose model. CONCLUSIONS: For a good prediction of tacrolimus pharmacokinetics, age, BSA, CYP3A4 and CYP3A5 genotype are important covariates. These covariates explained 30% of the variability in CL/F. The model proved effective in calculating the optimal tacrolimus dose based on these parameters and can be used to individualize the tacrolimus dose in the early period after transplantation.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Andrews LM, Hesselink DA, van Schaik RHN, et al. A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol. 2019. PMID: 30552703. doi:10.1111/bcp.13838

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。